Table 2: Demographic, clinical, and CEUS characteristics of the patients before and at 12 months of anti-TN therapy.

Patient numberGenderAgeDuration
Pso (yrs)
Duration
PsA (yrs)
TherapyMonth 0Month 12
TJCSJCDactylitisEnthesitisCEUSPASITJCSJCDactylitisEnthesitisCEUSPASI

1 F 37 22 2Adalimumab10 0 No No 20.2 10 0 No No 11.0
2 M 45 24 15Etanercept18 1 No No 33.7 0 0 No No 00.0
3 F 27 25 3Etanercept19 0 No Yes 30.0 0 0 No No 00.0
4 F 48 6<1Adalimumab48 7 Yes No 20.9 51 0 No Yes 20.0
5 M 55 3 3Adalimumab 4 2 Yes No 32.8 1 0 No No 10.0
6 F 47 27 1Adalimumab12 3 No Yes 310 4 0 No Yes 12.4
7 F 63 21 21Adalimumab11 2 No Yes 32.0 0 0 No No 11.6
8 F 64 24 3Etanercept 3 0 No Yes 33.1 0 0 No No 20.0
9 F 54 40 7Etanercept 3 2 No No 22.9 4 1 No No 01.9
10 F 66 32<1Etanercept10 6 No No 12.7 8 0 No No 00.8
11 M 48 4 1.5Etanercept17 2 Yes Yes31.2 1 1 No No 00.0
12 M 58 24 14Etanercept 1 1 No No 02.7 0 0 No No 00.0
13 M 41 23 1Etanercept 2 1 No No 22.6 0 0 No No 00.0
14 M 54 36 16Adalimumab 8 0 No No 19.610 0 No No 16.6
15 M 43 28 22Adalimumab17 6 No Yes 320.4 1 0 No Yes 00.0
16 F 59 46 20Etanercept 2 2 Yes No 03.2 0 0 No No 01.8
17 M 36 2 1.5Adalimumab11 4 No No21.2 0 0 No No 00.0
18 M 44 31 31Etanercept 4 4 No No22.8 0 0 No No 12.0
19 F 54 4 2Adalimumab15 3 No Yes32.415 0 No Yes 10.0
20 F 51 15<1Adalimumab 8 2 No Yes30.8 2 0 No No 10.0
21 M 62 10<1Etanercept 3 0 No No 22.6 1 1 No No 02.1
22 M 65 5 3Etanercept 3 2 Yes No 25.2 1 1 No No 12.1
23 M 69 19<1Etanercept 6 0 No No 05.9 0 0 No No 05.0
24 F 29 8 3Etanercept10 1 No No 10.2 0 0 No Yes 10.0
25 M 45 24 2Etanercept 9 2 Yes No34.5 0 0 No No 03.6

TJC: tender joint count; SJC: swollen joint count; CEUS: contrast-enhanced ultrasound; PASI: Psoriasis Area Severity Index.